Q4 Earnings Forecast for OmniAb Issued By HC Wainwright

OmniAb, Inc. (NASDAQ:OABI) – Equities research analysts at HC Wainwright issued their Q4 2025 earnings per share estimates for shares of OmniAb in a report issued on Wednesday, March 19th. HC Wainwright analyst J. Pantginis forecasts that the company will post earnings of ($0.15) per share for the quarter. HC Wainwright currently has a “Buy” rating and a $11.00 price target on the stock. The consensus estimate for OmniAb’s current full-year earnings is ($0.61) per share. HC Wainwright also issued estimates for OmniAb’s FY2029 earnings at ($0.29) EPS.

Separately, Benchmark cut their price objective on OmniAb from $8.00 to $6.00 and set a “buy” rating for the company in a report on Thursday.

OmniAb Trading Up 11.5 %

Shares of OABI stock opened at $2.53 on Friday. The firm’s fifty day moving average price is $3.34 and its two-hundred day moving average price is $3.77. OmniAb has a 1 year low of $2.23 and a 1 year high of $5.63. The firm has a market capitalization of $357.28 million, a P/E ratio of -4.08 and a beta of -0.14.

OmniAb (NASDAQ:OABI) last released its earnings results on Tuesday, March 18th. The company reported ($0.12) EPS for the quarter, beating the consensus estimate of ($0.13) by $0.01. OmniAb had a negative return on equity of 20.97% and a negative net margin of 308.78%. The firm had revenue of $10.80 million for the quarter, compared to analysts’ expectations of $10.13 million. During the same quarter in the previous year, the business posted ($0.14) EPS.

Institutional Inflows and Outflows

A number of hedge funds have recently modified their holdings of the stock. Atria Investments Inc acquired a new stake in shares of OmniAb during the 3rd quarter worth approximately $148,000. Intech Investment Management LLC bought a new stake in OmniAb during the third quarter worth $70,000. Charles Schwab Investment Management Inc. boosted its holdings in shares of OmniAb by 2.1% in the 3rd quarter. Charles Schwab Investment Management Inc. now owns 787,522 shares of the company’s stock valued at $3,331,000 after purchasing an additional 16,219 shares in the last quarter. FMR LLC increased its stake in shares of OmniAb by 10.6% in the 3rd quarter. FMR LLC now owns 138,813 shares of the company’s stock valued at $587,000 after purchasing an additional 13,324 shares during the last quarter. Finally, BBR Partners LLC raised its holdings in shares of OmniAb by 250.0% during the 3rd quarter. BBR Partners LLC now owns 70,000 shares of the company’s stock worth $296,000 after buying an additional 50,000 shares in the last quarter. Institutional investors own 72.08% of the company’s stock.

Insider Transactions at OmniAb

In other OmniAb news, insider Charles S. Berkman sold 25,489 shares of OmniAb stock in a transaction on Tuesday, January 21st. The stock was sold at an average price of $3.24, for a total value of $82,584.36. Following the completion of the transaction, the insider now directly owns 343,190 shares of the company’s stock, valued at $1,111,935.60. The trade was a 6.91 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, Director John L. Higgins bought 125,750 shares of the business’s stock in a transaction dated Thursday, March 20th. The shares were bought at an average price of $2.35 per share, with a total value of $295,512.50. Following the completion of the transaction, the director now owns 2,762,887 shares in the company, valued at approximately $6,492,784.45. This trade represents a 4.77 % increase in their position. The disclosure for this purchase can be found here. In the last three months, insiders sold 112,260 shares of company stock worth $376,601. 8.60% of the stock is owned by company insiders.

About OmniAb

OmniAb, Inc, a biotechnology company, engages in the discovery and provision of therapeutic antibody discovery technologies in the United States. The company's technology platform creates and screens diverse antibody repertoires and identify optimal antibodies for partners' drug development efforts.